Heart Protection Drug Study After Heart Attack
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a diabetes medication called ertugliflozin can help protect your heart function after a heart attack. Researchers want to see if starting this medicine early (within 3 days) helps your heart recover better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have type 2 diabetes (not type 1)
- You have had your first heart attack and can start the study within 72 hours
- Your kidneys are working (not on dialysis or had a transplant)
- You have not taken other SGLT2 inhibitor drugs in the past 4 weeks
- Your blood pressure is stable enough for the study (systolic at least 90 mmHg)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This study tests whether a diabetes medication can improve artery health and heart function after a heart attack. It is for people who have had a STEMI and also have diabetes or a weakened heart pump.
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
This study looks at whether certain diabetes medicines, called SGLT2 inhibitors and GLP-1 receptor agonists, can help protect the heart in people with type 2 diabetes. It may help you understand if these treatments are a good option for your heart health.
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
Hear when a new Type 2 Diabetes Mellitus Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.